Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Nat Commun ; 15(1): 818, 2024 Jan 27.
Article in English | MEDLINE | ID: mdl-38280869

ABSTRACT

Animal studies have demonstrated the ability of pancreatic acinar cells to transform into pancreatic ductal adenocarcinoma (PDAC). However, the tumorigenic potential of human pancreatic acinar cells remains under debate. To address this gap in knowledge, we expand sorted human acinar cells as 3D organoids and genetically modify them through introduction of common PDAC mutations. The acinar organoids undergo dramatic transcriptional alterations but maintain a recognizable DNA methylation signature. The transcriptomes of acinar organoids are similar to those of disease-specific cell populations. Oncogenic KRAS alone do not transform acinar organoids. However, acinar organoids can form PDAC in vivo after acquiring the four most common driver mutations of this disease. Similarly, sorted ductal cells carrying these genetic mutations can also form PDAC, thus experimentally proving that PDACs can originate from both human acinar and ductal cells. RNA-seq analysis reveal the transcriptional shift from normal acinar cells towards PDACs with enhanced proliferation, metabolic rewiring, down-regulation of MHC molecules, and alterations in the coagulation and complement cascade. By comparing PDAC-like cells with normal pancreas and PDAC samples, we identify a group of genes with elevated expression during early transformation which represent potential early diagnostic biomarkers.


Subject(s)
Carcinoma, Pancreatic Ductal , Pancreatic Neoplasms , Animals , Humans , Transcriptome , Pancreatic Neoplasms/pathology , Carcinoma, Pancreatic Ductal/pathology , Carcinogenesis/pathology , Acinar Cells/metabolism , Gene Expression Profiling , Proto-Oncogene Proteins p21(ras)/genetics , Proto-Oncogene Proteins p21(ras)/metabolism
2.
J Clin Pathol ; 77(3): 151-156, 2024 Feb 19.
Article in English | MEDLINE | ID: mdl-38053274

ABSTRACT

AIMS: There is great variability in the assessment and reporting of fat in frozen sections of donor liver biopsies. The Banff Working Group has proposed a novel method and definition for scoring large droplet fat (LDF) in donor liver biopsies. This study compares the Banff method with a simpler Average of Fields (AF) method and evaluates the impact of different LDF definitions. METHODS: Three pathologists assessed percentage of LDF (LDF%) in 10 donor liver biopsies using Banff and AF methods, applying the Banff LDF definition (cell distention with a single droplet larger than adjacent hepatocytes). Additionally, LDF% by the AF method was compared using two LDF definitions: Banff definition versus LDF definition 2 (single fat droplet occupying greater than half of a hepatocyte with nuclear displacement). RESULTS: Intraobserver concordance between the Banff and AF methods was similar for all three pathologists (kappa 0.76-1). Both methods exhibited 70% interobserver concordance, and there was substantial agreement (kappa 0.68) in the LDF% among the three pathologists for both methods. Comparing the two LDF definitions, results were significantly lower with the Banff definition; LDF >50% was observed in four cases with LDF definition 2 but none of the cases with the Banff definition. CONCLUSIONS: There is high interobserver and intraobserver concordance of LDF% between the Banff and AF methods. LDF% determined by the Banff definition was lower than with LDF definition 2, and needs to be validated based on graft outcome before it can be recommended for clinical use.


Subject(s)
Liver Transplantation , Humans , Observer Variation , Frozen Sections , Living Donors , Biopsy , Liver/pathology
3.
Cancer Sci ; 114(6): 2400-2413, 2023 Jun.
Article in English | MEDLINE | ID: mdl-36916958

ABSTRACT

Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K) acetyltransferases 5 (TIP60, also known as KAT5) is reportedly implicated in cancer development and maintenance, although its function in lung cancer remains controversial. Here we demonstrate that TIP60 knockdown in non-small cell lung cancer cell lines decreased tumor cell growth, migration, and invasion. Furthermore, analysis of a mouse lung cancer model with lung-specific conditional Tip60 knockout revealed suppressed tumor formation relative to controls, but no apparent effects on normal lung homeostasis. RNA-seq and ChIP-seq analyses of inducible TIP60 knockdown H1975 cells relative to controls revealed transglutaminase enzyme (TGM5) as downstream of TIP60. Investigation of a connectivity map database identified several candidate compounds that decrease TIP60 mRNA, one that suppressed tumor growth in cell culture and in vivo. In addition, TH1834, a TIP60 acetyltransferase inhibitor, showed comparable antitumor effects in cell culture and in vivo. Taken together, suppression of TIP60 activity shows tumor-specific efficacy against lung cancer, with no overt effect on normal tissues. Our work suggests that targeting TIP60 could be a promising approach to treating lung cancer.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Animals , Mice , Carcinogenesis/genetics , Carcinoma, Non-Small-Cell Lung/genetics , Cell Transformation, Neoplastic/genetics , Histone Acetyltransferases/genetics , Histone Acetyltransferases/metabolism , Lung Neoplasms/genetics , Humans
4.
Mod Pathol ; 36(5): 100117, 2023 05.
Article in English | MEDLINE | ID: mdl-36805791

ABSTRACT

Fundic gland polyps (FGPs) develop sporadically (frequently after proton pump inhibitor therapy) or in the setting of a hereditary polyposis syndrome, such as familial adenomatous polyposis (FAP). FAP-related FGPs often demonstrate low-grade dysplasia (LGD) and are frequently associated with APC mutations, even in the absence of dysplasia. Sporadic FGPs with dysplasia are molecularly similar to FAP-related FGPs and demonstrate frequent mutations in APC gene. Despite having similar molecular alterations with colorectal and other adenomatous precursor lesions in the gastrointestinal (GI) tract, FGPs rarely progress to advanced gastric neoplasia (high-grade dysplasia [HGD] or adenocarcinoma), and their role in gastric tumorigenesis remains unclear but likely limited. The clinicopathologic features of 192 patients diagnosed with FGPs, including 86 with FAP-related FGPs (33 with dysplastic FGPs and 53 with nondysplastic FGPs) and 106 with sporadic FGPs (12 with dysplastic FGPs and 94 with nondysplastic FGPs), were analyzed. DNA flow cytometry was performed on 111 FAP-related FGP biopsies, including 32 FGPs with LGD and 79 nondysplastic FGPs, to assess the presence of abnormal DNA content (ie, aneuploidy or elevated 4N fraction). Moreover, 40 sporadic FGP biopsies, including 14 dysplastic (13 LGD and 1 HGD) and 26 nondysplastic FGPs, were examined for DNA content abnormality. Patients with FAP and nondysplastic FGPs were more likely to be younger (mean age, 32 years) and present with multiple FGPs (92%, defined as having ≥2 FGPs) than those with sporadic nondysplastic FGPs (61 years and 65%, respectively; P < .001). They also recorded higher rates of previous or concurrent gastric epithelial dysplasia not occurring in a FGP (8%, P = .016), nongastric GI dysplasia (96%, P < .001), and nongastric GI malignancy (17%, P = .001) compared with those with sporadic nondysplastic FGPs (0%, 52%, and 2%, respectively). The sporadic group was more frequently associated with proton pump inhibitor therapy (78%, P < .001), gastric intestinal metaplasia (24%, P = .004), and a family history of gastric cancer (10%, P = .027) than the FAP group (19%, 6%, and 0%, respectively). Almost all FAP-related FGPs had a polypoid endoscopic appearance (98% vs 84% for sporadic FGPs; P = .009). The mean size of the largest FAP-related FGPs (0.5 cm) was similar to that of sporadic FGPs (0.7 cm) (P = .069). None of the 147 patients with FAP-related or sporadic nondysplastic FGPs were associated with subsequent detection of advanced gastric neoplasia within a mean follow-up time of 54 months (range, <1 to 277 months). However, 2 (4%) of the 45 patients with FAP-related or sporadic dysplastic FGPs developed advanced gastric neoplasia within a mean follow-up time of 59 months (range, <1 to 236 months). One (3%) of the 33 patients with FAP and dysplastic FGPs developed signet ring cell adenocarcinoma, whereas 1 (8%) of the 12 patients with sporadic dysplastic FGPs developed HGD (P = .445). However, none of the FAP-related and sporadic FGP biopsies, regardless of the presence or absence of dysplasia, demonstrated DNA content abnormality. In conclusion, FGPs lack large-scale chromosomal changes that are characteristic of the typical adenoma-carcinoma sequence involved in the development of other GI malignancies. Progression to advanced gastric neoplasia is rare in FGPs, which may be partly explained by the apparent lack of the chromosomal instability phenotype in these lesions.


Subject(s)
Adenocarcinoma , Adenoma , Adenomatous Polyposis Coli , Stomach Neoplasms , Humans , Stomach Neoplasms/genetics , Stomach Neoplasms/pathology , Proton Pump Inhibitors , Adenomatous Polyposis Coli/genetics , Adenomatous Polyposis Coli/pathology , Hyperplasia , Adenocarcinoma/genetics
5.
Pancreas ; 46(9): 1202-1207, 2017 10.
Article in English | MEDLINE | ID: mdl-28902792

ABSTRACT

OBJECTIVE: We aimed to evaluate the contribution of acinar-to-ductal metaplasia (ADM) to the accumulation of cells with a ductal phenotype in cultured human exocrine pancreatic tissues and reveal the underlying mechanism. METHODS: We sorted and cultured viable cell populations in human exocrine pancreatic tissues with a flow cytometry-based lineage tracing method to evaluate possible mechanisms of ADM. Cell surface markers, gene expression pattern, and sphere formation assay were used to examine ADM. RESULTS: A large proportion of acinar cells gained CD133 expression during the 2-dimensional culture and showed down-regulation of acinar markers and up-regulation of ductal markers, assuming an ADM phenotype. In a serum-free culture condition, ADM induction was mainly dependent on transforming growth factor ß (TGF-ß) secreted from cultured ductal cells. Human acinar cells when cultured alone for a week in a serum-free condition do not undergo ADM. However, serum may contain other factors besides TGF-ß to induce ADM in human acinar cells. In addition, we found that TGF-ß cannot induce ADM of murine acinar cells. CONCLUSIONS: Ductal cells are the major source of TGF-ß that induces ADM in cultured human exocrine pancreatic tissues. This culture system might be a useful model to investigate the mechanism of ADM in human cells.


Subject(s)
Acinar Cells/metabolism , Pancreas, Exocrine/metabolism , Pancreatic Ducts/metabolism , Transforming Growth Factor beta/metabolism , Acinar Cells/pathology , Animals , Cells, Cultured , Flow Cytometry , Gene Expression , Humans , Metaplasia , Mice , Pancreatic Ducts/pathology , Paracrine Communication , Reverse Transcriptase Polymerase Chain Reaction , Tissue Culture Techniques , Transforming Growth Factor beta/genetics
6.
Ann Surg Oncol ; 24(11): 3446-3455, 2017 Oct.
Article in English | MEDLINE | ID: mdl-27882471

ABSTRACT

BACKGROUND: The expression of Fos-related antigen 1 (Fra-1) affects tumor progression, migration, and invasion. In this study, we identified the genes regulated by Fra-1 in esophageal squamous cell carcinoma (ESCC). METHODS: We constructed Fra-1 knockdown models via the transfection of small interfering RNA (siRNA) into ESCC cell lines (TE10, TE11). The expression levels of the genes in the knockdown models were analyzed using a microarray and a Biobase Upstream Analysis, while the expression levels of the candidate genes in the primary tumors of surgical specimens obtained from ESCC patients were determined using real-time polymerase chain reaction (PCR) and immunohistochemical staining. The clinicopathological features were then analyzed. RESULTS: The Biobase Upstream Analysis showed the high-mobility-group protein-1 (HMGA1) to be a significant gene regulated by Fra-1. Actual binding of Fra-1 to the promotor region of HMGA1 was revealed in subsequent chromatin immunoprecipitation PCR experiments. Patients with a positive HMGA1 expression had a poor prognosis, and a multivariate analysis demonstrated a positive HMGA1 expression to be a significant independent prognostic factor. CONCLUSION: HMGA1 is regulated by Fra-1 in ESCC, and the HMGA1 expression is significantly associated with a poor prognosis in ESCC patients. Downregulation of the HMGA1 expression may become a practical treatment strategy against ESCC in the future.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/secondary , Esophageal Neoplasms/pathology , Gene Expression Regulation, Neoplastic , HMGA1a Protein/metabolism , Proto-Oncogene Proteins c-fos/metabolism , Biomarkers, Tumor/genetics , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/surgery , Cell Movement , Cell Proliferation , Esophageal Neoplasms/genetics , Esophageal Neoplasms/metabolism , Esophageal Neoplasms/surgery , HMGA1a Protein/genetics , Humans , Lymphatic Metastasis , Neoplasm Invasiveness , Prognosis , Proto-Oncogene Proteins c-fos/genetics , Tumor Cells, Cultured
7.
Sci Rep ; 6: 30904, 2016 08 03.
Article in English | MEDLINE | ID: mdl-27485764

ABSTRACT

Animal studies suggest that pancreatitis-induced acinar-to-ductal metaplasia (ADM) is a key event for pancreatic ductal adenocarcinoma (PDAC) initiation. However, there has not been an adequate system to explore the mechanisms of human ADM induction. We have developed a flow cytometry-based, high resolution lineage tracing method and 3D culture system to analyse ADM in human cells. In this system, well-known mouse ADM inducers did not promote ADM in human cells. In contrast, TGF-ß1 efficiently converted human acinar cells to duct-like cells (AD) in a SMAD-dependent manner, highlighting fundamental differences between the species. Functionally, AD cells gained transient proliferative capacity. Furthermore, oncogenic KRAS did not induce acinar cell proliferation, but did sustain the proliferation of AD cells, suggesting that oncogenic KRAS requires ADM-associated-changes to promote PDAC initiation. This ADM model provides a novel platform to explore the mechanisms involved in the development of human pancreatic diseases.


Subject(s)
Acinar Cells/pathology , Metaplasia/pathology , Pancreas, Exocrine/pathology , Transforming Growth Factor beta1/metabolism , Acinar Cells/metabolism , Cells, Cultured , Humans , Metaplasia/metabolism , Pancreas, Exocrine/metabolism , Signal Transduction
8.
Ann Surg Oncol ; 23(1): 312-20, 2016 Jan.
Article in English | MEDLINE | ID: mdl-25791791

ABSTRACT

BACKGROUND: The expression of genes can be influenced by the balance of histone acetylation and/or histone demethylation, with an imbalance of these processes possibly observed in many cancers. The histone demethylase LSD1 inhibitor activity is associated with selective transcriptional regulation and alterations in the gene expression. However, the exact mechanisms underlying the antitumor effects of LSD1 inhibitors are not fully understood. METHODS: The antitumor effects of NCL1, an LSD1 inhibitor, in esophageal squamous cell cancer (ESCC) cell lines were evaluated. A comprehensive analysis of the changes in the gene expression in ESCC cell lines induced by NCL1 was carried out using a microarray analysis. A loss-of-function assay using a siRNA analysis was performed to examine the oncogenic function of the gene. RESULTS: NCL1 strongly inhibited the cell growth of T.Tn and TE2 ESCC cells and induced apoptosis. According to the microarray analysis, 81 genes in the T.Tn cells and 149 genes in the TE2 cells were up- or down-regulated 2-fold or more by NCL1 exposure. Among these genes, 27 were contained in both cell lines and exhibited similar expression patterns. PHLDB2, one of the genes down-regulated by NCL1, was overexpressed in the ESCC tumor tissues. Moreover, a high expression level of PHLDB2 was found to be significantly correlated with poor prognosis. CONCLUSIONS: The present observations of the comprehensive analysis of the gene expression levels provide insight into the mechanisms underlying the antitumor effects of LSD1 inhibitors in ESCC patients.


Subject(s)
Apoptosis/drug effects , Carcinoma, Squamous Cell/prevention & control , Cell Proliferation/drug effects , Esophageal Neoplasms/prevention & control , Gene Expression Regulation, Neoplastic/drug effects , Histone Deacetylase Inhibitors/pharmacology , Histone Demethylases/antagonists & inhibitors , Biomarkers, Tumor/genetics , Blotting, Western , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Cell Movement/drug effects , Esophageal Neoplasms/genetics , Esophageal Neoplasms/pathology , Gene Expression Profiling , Histone Demethylases/genetics , Histone Demethylases/metabolism , Humans , Immunoenzyme Techniques , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
9.
PLoS One ; 10(4): e0122849, 2015.
Article in English | MEDLINE | ID: mdl-25850029

ABSTRACT

INTRODUCTION: Photodynamic therapy (PDT) is a less invasive option for cancer treatment that has evolved through recent developments in nanotechnology. We have designed and synthesized a novel liposome system that includes an indocyanine green (ICG) derivative, ICG-C18, in its bilayer. In addition to its use as an optical imager to visualize blood, lymphatic, and bile flow, ICG has also been used as an optical sensitizer. In the present report, we evaluate the use of our novel liposome system, LP-ICG-C18, in PDT for squamous cell carcinoma in an autologous murine model. MATERIALS AND METHODS: An excitation pulse beam (300 µJ/pulse) of a single band (800 nm) was used for sensitization. The cytotoxicity of the photodynamic therapy was evaluated in terms of cellular morphology changes, methyl thiazolyl tetrazolium (MTT) assay results, and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL) staining. We tested the enhanced permeability and retention effect of LP-ICG-C18 in tumor-bearing C3H/He mice using a near-infrared fluorescence imaging system and fluorescence microscopy. We also examined the antitumor effect of PDT by measuring tumor volume in tumor-bearing mice. RESULTS: Cell death and apoptosis were only observed in the PDT group receiving LP-ICG-C18. LP-ICG-C18 itself had no cytotoxic activity and showed good biocompatibility. LP-ICG-C18 accumulated on the tumor 24 hours after injection and was retained for approximately 3 weeks. Tumor cell apoptosis following PDT with LP-ICG-C18 was also observed under optical microscopy, MTT assay, and TUNEL staining. CONCLUSION: These findings suggest that LP-ICG-C18 may be an effective intervening material in PDT for malignant disease.


Subject(s)
Carcinoma, Squamous Cell/drug therapy , Indocyanine Green/administration & dosage , Indocyanine Green/pharmacology , Infrared Rays , Photochemotherapy , Photosensitizing Agents/administration & dosage , Photosensitizing Agents/pharmacology , Animals , Biological Transport , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Cell Transformation, Neoplastic , Chemistry, Pharmaceutical , Female , Hydrophobic and Hydrophilic Interactions , Indocyanine Green/chemistry , Indocyanine Green/metabolism , Liposomes , Mice , Photosensitizing Agents/chemistry , Photosensitizing Agents/metabolism , Temperature
10.
Anticancer Res ; 35(3): 1353-9, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25750285

ABSTRACT

BACKGROUND/AIM: Although conventional staging laparoscopy (SL) has improved the diagnostic accuracy of peritoneal dissemination, novel technology is needed to increase the sensitivity of SL. We herein describe a new imaging method employing near-infrared (NIR) fluorescence imaging using a liposomal synthesized indocyanine green (ICG) liposomal derivative, LP-ICG-C18. METHODS AND RESULTS: LP-ICG-C18 is a NIR-photoactivating probe in which an ICG fluorophore is covalently conjugated with a phospholipid moiety. Nude mice were intraperitoneally injected with gastric cancer cells. Twelve days later, the mice were given intravenous injections of LP-ICG-C18 at a dose of 0.15 mg/kg. A NIR imaging system was used to identify the disseminated tumors. The disseminated nodules in mice were detected without any difficulties. Disseminated tumor nodules were collected from mice with or without injections of liposomal formulation and were transferred into the swine peritoneal cavity. The nodules in the swine peritoneal cavity were clearly and promptly defined by the NIR imaging system. CONCLUSION: NIR-fluorescing liposomal probes can effectively target peritoneal disseminated tumors and can be easily detected by a NIR imaging system. These results warrant future clinical trials of our imaging system and may contribute to a more precise diagnosis and therapeutic approach for gastric cancer patients.


Subject(s)
Indocyanine Green/administration & dosage , Laparoscopy/methods , Peritoneal Neoplasms/diagnosis , Peritoneal Neoplasms/secondary , Stomach Neoplasms/pathology , Animals , Cell Line, Tumor , Female , Humans , Liposomes , Mice , Mice, Inbred BALB C , Optical Imaging , Swine
11.
Int J Oncol ; 46(3): 1059-66, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25501018

ABSTRACT

The aim of this study was to clarify the importance of microRNA­375 (miR­375) expression in patients with esophageal squamous cell carcinoma (ESCC) and to examine the in vivo antitumor effects of miR­375 in a model of ESCC using a non­viral delivery system. We estimated the miR­375 and LDHB and AEG­1/MTDH mRNA expression of the ESCC tumors from 85 patients. The correlation between the miR­375 expression and clinicopathological features, including the prognosis, were evaluated. The presence of high miR­375 expression was associated with lymphatic vessel invasion, while a low expression of miR­375 significantly correlated with a poor prognosis for the 85 ESCC patients. We also found that there was a significant inverse correlation between the expression of miR­375 and that of LDHB. Before the examination of miR­375 in the in vivo assay, we confirmed that atelocollagen prolonged the accumulation of miRNA by using fluorescently­labeled miRNA and an in vivo imaging system. We injected the miR­375/atelocollagen complex or a control­miRNA/atelocollagen complex into mice bearing TE2 and T.Tn xenografts via subcutaneous (s.c.) injections. The growth of both the TE2 and T.Tn tumors in the miR­375 groups was significantly suppressed compared with that in the control­miRNA groups. In addition, The LDHB mRNA expression of TE2 xenografts was significantly downregulated after miR­375 treatment. In conclusion, it might be possible for the level of miR­375 expression to be a utilized as a prognostic indicator for ESCC patients. The administration of miR­375 using a non­viral delivery might represent a powerful new treatment for ESCC.


Subject(s)
Carcinoma, Squamous Cell/genetics , Esophageal Neoplasms/genetics , Gene Expression Regulation, Neoplastic , MicroRNAs/genetics , Aged , Animals , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Cell Adhesion Molecules/genetics , Collagen/administration & dosage , Drug Delivery Systems/methods , Esophageal Neoplasms/pathology , Esophageal Neoplasms/surgery , Esophageal Squamous Cell Carcinoma , Female , Humans , Isoenzymes/genetics , L-Lactate Dehydrogenase/genetics , Male , Membrane Proteins , Mice, Inbred BALB C , MicroRNAs/administration & dosage , Middle Aged , Prognosis , RNA-Binding Proteins , Xenograft Model Antitumor Assays
12.
Surg Today ; 45(2): 247-52, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24890800

ABSTRACT

Gastrointestinal stromal tumors (GISTs) rarely arise in the esophagus, where carcinoma is the most common malignant neoplasm and leiomyoma is the most common benign tumor. Because of their rarity, the clinical course and treatment of esophageal GISTs are poorly understood. These lesions are generally thought to carry a poor prognosis, making the differential diagnosis of other common mesenchymal neoplasms essential, for both prognostic and therapeutic reasons. We report a case of successfully resected giant esophageal GIST, thought to be the largest resected GIST reported in Japan. The patient was a 65-year-old woman, in whom upper gastrointestinal endoscopy found a 180-mm submucosal tumor in the lower thoracic esophagus, extending just below the aortic arch. We diagnosed esophageal GIST, and the patient underwent middle and lower esophagectomy via left thoracotomy, followed by gastric tube reconstruction. The tumor was resected completely. Histopathological and immunohistochemical staining confirmed that the tumor was a high-risk lesion, and treatment with imatinib was initiated. Computed tomography showed liver metastasis 5 months later, but the patient is doing well 24 months after surgery.


Subject(s)
Esophageal Neoplasms/surgery , Gastrointestinal Stromal Tumors/surgery , Aged , Benzamides/administration & dosage , Endoscopy, Gastrointestinal , Esophageal Neoplasms/diagnosis , Esophageal Neoplasms/pathology , Esophagectomy , Female , Gastrointestinal Stromal Tumors/pathology , Humans , Imatinib Mesylate , Liver Neoplasms/secondary , Piperazines/administration & dosage , Pyrimidines/administration & dosage , Plastic Surgery Procedures , Thoracotomy , Treatment Outcome
13.
Int Surg ; 99(6): 846-50, 2014.
Article in English | MEDLINE | ID: mdl-25437598

ABSTRACT

Short gastric vessel division (SGVD) has been performed as a part of fundoplication for achalasia. However, whether or not SGVD is necessary is still unknown. Forty-six patients with achalasia who underwent a laparoscopic surgery with or without SGVD were analyzed. A questionnaire was administered to assess the postoperative improvement. Regarding improvement of dysphagia and postoperative reflux, there were no significant differences between SGVD (+) group and SGVD (-) group (P = 0.588 and P = 0.686, respectively). Nineteen patients (95%) in the SGVD (+) group and 24 (92%) in the SGVD (-) group answered that the surgery was satisfactory (P = 0.756). In the SGVD (+) group, the pre- and postsurgical body weight increase was +7.3%. In the SGVD (-) group, it was 8.2%. There was no significant difference of body weight increase between the 2 groups (P = 0.354). SGVD is not always required in laparoscopic surgery for achalasia.


Subject(s)
Esophageal Achalasia/surgery , Laparoscopy/methods , Adult , Female , Fundoplication , Humans , Iatrogenic Disease , Male , Manometry , Middle Aged , Surveys and Questionnaires , Treatment Outcome
14.
Oncol Rep ; 32(6): 2373-9, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25242303

ABSTRACT

The aim of this study was to assess whether modulated electro-hyperthermia (mEHT) can induce an abscopal effect and thereby enhance the antitumor effects of immunotherapy. We used an intratumoral dendritic cell (DC) injection and mEHT to treat C3H/He mice inoculated with squamous cell carcinoma SCCVII cells in the left leg, and we assessed the whole body antitumor effects. Tumors were examined every two or three days in order to assess growth inhibition. The tumor-draining lymph nodes were removed to enable flow cytometric analysis of CD3+ and CD8+ cells, whereas immunohistochemistry was used to assess CD8, S100 and Foxp3 expression in the tumors. Additionally, GP96 expression in the tumors from the different treatment groups was measured. In the control group, the mean tumor volume was larger than that in other groups. These results indicated that the combination therapy of an intratumoral DC injection and mEHT evoked systemic antitumor activity. A larger number of CD3+ and CD8+ cells were detected by flow cytometric analysis in the DC plus mEHT treatment group. Tumor tissue immunostaining showed that CD8 and S100 were more strongly expressed in the DC plus mEHT treatment group, although Foxp3 expression was much higher in the control group. The GP96 gene expression level in the mEHT group was significantly different from the expression level in the control group. An abscopal effect may be induced by mEHT, and the effect of immunotherapy with DCs was strongly enhanced by the overexpression of GP96. GP96 is thought to be one of the molecules explaining the abscopal effect. Direct intratumoral administration of DCs and mEHT may be a feasible future treatment strategy.


Subject(s)
Carcinoma, Squamous Cell/therapy , Dendritic Cells/transplantation , Hyperthermia, Induced , Thoracic Neoplasms/therapy , Animals , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/secondary , Combined Modality Therapy , Dendritic Cells/immunology , Female , Humans , Immunotherapy , Membrane Glycoproteins/metabolism , Mice, Inbred C3H , T-Lymphocytes/immunology , Thoracic Neoplasms/immunology , Thoracic Neoplasms/secondary
15.
Oncology ; 87(6): 351-63, 2014.
Article in English | MEDLINE | ID: mdl-25195536

ABSTRACT

OBJECTIVE: The aim of this study was to identify alternative compounds to the tumor suppressor miR-375 using the connectivity map (CMAP) and to validate the antitumor effects of the identified drugs in esophageal squamous cell carcinoma (ESCC). METHODS: Gene profiling of miR-375-treated TE2 and T.Tn cells was applied in order to search the CMAP database. Among the compounds identified using the CMAP, we focused on 8 drugs [(-)-epigallocatechin-3-gallate, metformin, rosiglitazone among others], excluding 2 drugs among the top 10 compounds. We evaluated whether these compounds possess tumor-suppressive functions in ESCC. RESULTS: A cytotoxicity assay showed that the sensitivity of TE2 and T.Tn cells treated with the 8 compounds was evaluated based on IC50 values of 42.9 µM to 3.8 mM. A cell cycle analysis revealed that the percentage of TE2 and T.Tn cells incubated with 6 compounds in the G0/G1 phase or the G2/M phase increased by approximately 40-80%. A TUNEL assay showed that the percentages of apoptotic cells treated with almost all compounds were significantly increased (p < 0.05) compared with the control cells. CONCLUSION: The CMAP database is a useful tool for identifying compounds affecting the same molecular pathways, particularly products that are difficult to apply via practical approaches, such as microRNAs.


Subject(s)
Antineoplastic Agents/pharmacology , Carcinoma, Squamous Cell/drug therapy , Cytotoxins/pharmacology , Esophageal Neoplasms/drug therapy , MicroRNAs/drug effects , Tumor Suppressor Proteins/drug effects , Apoptosis/drug effects , Benzocaine/pharmacology , Betazole/pharmacology , Catechin/analogs & derivatives , Catechin/pharmacology , Cell Line, Tumor/drug effects , Chenodeoxycholic Acid/pharmacology , DNA Primers , Humans , In Situ Nick-End Labeling , Metformin/pharmacology , MicroRNAs/metabolism , Nizatidine/pharmacology , Organophosphates/pharmacology , Proline/analogs & derivatives , Proline/pharmacology , Protein Array Analysis , Real-Time Polymerase Chain Reaction , Rosiglitazone , Thiazolidinediones/pharmacology , Transcriptome , Transfection , Tumor Suppressor Proteins/genetics
16.
Int J Oncol ; 44(4): 1146-52, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24535229

ABSTRACT

Cyclooxygenase-2 (COX-2) is a key enzyme of prostaglandin (PG) synthesis that has been demonstrated to be overexpressed in several types of cancers. The function of COX-2 in tumor progression has been recently elucidated. In tumors in which COX-2 is overexpressed, the antitumor effects are suppressed. We examined the effects of celecoxib, a COX-2 inhibitor, in enhancing the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma (ESCC) by reducing the COX-2 activity. We used the human esophageal squamous cell lines TE2 and T.Tn treated with celecoxib and 5-FU/radiation, after which cell viability assays were performed. Changes in the expressions of dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT) mRNA and PGE2 were also measured. In addition, apoptotic changes, and the invasion and migration activity in both the celecoxib and 5-FU treated cells were evaluated. The experiments showed that T.Tn and TE2 proliferation was strongly inhibited by the combination of 5-FU/radiation and the COX-2 inhibitor. Inhibiting the COX-2 activity induced a reduction in PGE2 levels in TE2/T.Tn cells. Following treatment with the COX-2 inhibitor and 5-FU, the OPRT expression was upregulated and the DPD expression was downregulated in the resistant cells. In addition, the combination treatment with the COX-2 inhibitor and 5-FU markedly inhibited both the cell invasion and migration activity. Therefore, COX-2 inhibitors can be useful enhancers of antitumor drugs and radiotherapy for ESCC.


Subject(s)
Carcinoma, Squamous Cell/drug therapy , Cyclooxygenase 2 Inhibitors/pharmacology , Cyclooxygenase 2/metabolism , Esophageal Neoplasms/drug therapy , Fluorouracil/pharmacology , Pyrazoles/pharmacology , Sulfonamides/pharmacology , Antimetabolites, Antineoplastic/pharmacology , Apoptosis/drug effects , Carcinoma, Squamous Cell/radiotherapy , Celecoxib , Cell Line, Tumor , Cell Movement/drug effects , Dihydrouracil Dehydrogenase (NADP)/biosynthesis , Dihydrouracil Dehydrogenase (NADP)/genetics , Esophageal Neoplasms/radiotherapy , Esophageal Squamous Cell Carcinoma , Humans , Neoplasm Invasiveness , Orotate Phosphoribosyltransferase/biosynthesis , Orotate Phosphoribosyltransferase/genetics , Prostaglandins/biosynthesis , RNA, Messenger/biosynthesis , Radiation-Sensitizing Agents/pharmacology
17.
Jpn J Clin Oncol ; 44(2): 168-71, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24302758

ABSTRACT

OBJECTIVE: Extravasation, the accidental leakage of an anticancer agent from a vessel into the surrounding tissues, can lead to irreversible local injuries and severe disability. Despite its considerable clinical importance, evidence-based information on extravasation in chemotherapy is lacking. This study characterized the clinical features of extravasation and identified issues to be resolved in current cancer chemotherapy performed in outpatient settings. METHODS: We retrospectively reviewed the medical charts of patients who received chemotherapy and sustained extravasation in our Outpatient Chemotherapy Clinic from April 2007 to August 2012. Chemotherapy administration and extravasation management procedures were standardized using the in-house chemotherapy guideline. RESULTS: Among 43 557 patients who received chemotherapy, 35 (0.08%) experienced extravasation. The duration between the start of infusion and extravasation was >2 h in 28 (80.0%) patients. The severity of extravasation was Grades 1, 2 and 3 in 28, 2 and 5 patients, respectively-three of whom were associated with port trouble. The contributing factor for extravasation was walking in 11 (31.4%) patients. All extravasations were cured without surgical intervention by management according to our guidelines. CONCLUSIONS: The incidence of extravasation is as low as 0.08%, using our in-house chemotherapy guideline. Extravasation from implanted ports tends to be severe.


Subject(s)
Ambulatory Care Facilities/statistics & numerical data , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Cancer Care Facilities/statistics & numerical data , Extravasation of Diagnostic and Therapeutic Materials/epidemiology , Adult , Aged , Extravasation of Diagnostic and Therapeutic Materials/therapy , Female , Humans , Incidence , Japan/epidemiology , Male , Medical Records , Middle Aged , Patient Care Team , Retrospective Studies , Risk Factors , Treatment Outcome
18.
Surg Today ; 43(4): 446-51, 2013 Apr.
Article in English | MEDLINE | ID: mdl-22706784

ABSTRACT

Adenocarcinoma arising from heterotopic gastric mucosa (HGM) is exceedingly rare. This report presents the case of a 57-year-old male who presented with the chief complaint of dysphagia. Endoscopy and computed tomography revealed a locally advanced tumor of the cervical esophagus and swollen mediastinal lymph nodes. He underwent chemoradiotherapy followed by esophagectomy with three-field lymph node dissection. The resected tumor was a circumferentially scarred lesion located 1.5 cm from the proximal margin. The tumor was identified to be a well-differentiated adenocarcinoma arising from HGM with invasion to the muscularis propria. Postoperative chemoradiotherapy was performed because positive surgical margins were observed in the resected tissue. The patient has remained alive for more than 4 years after surgery, without any evidence of recurrence.


Subject(s)
Adenocarcinoma/pathology , Choristoma/pathology , Esophageal Neoplasms/pathology , Gastric Mucosa , Humans , Male , Middle Aged
19.
Ann Surg ; 257(6): 1032-8, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23108117

ABSTRACT

OBJECTIVES: T1 esophageal squamous cell carcinoma (ESCC) has a low, but still present, risk of lymph node (LN) metastasis. Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) is often applied for T1 ESCC. To achieve successful treatment by EMR/ESD, the risk of LN metastases, LN recurrence, and hematological recurrence need to be better understood. The aim of this study was to determine the precise risk for metastasis in T1 ESCC. METHODS: We divided 295 patients with T1 ESCC who underwent surgery and/or ESD/EMR into 6 categories (m1, m2, m3, sm1, sm2, and sm3). Their risks of LN metastasis, LN recurrence, hematological recurrence, and the outcome were determined. RESULTS: The rates of LN metastasis and LN recurrence were 0% in m1 and m2, 9% in m3, 16% in sm1, 35% in sm2, and 62% in sm3 cases. The incidence of hematological recurrence was 0% in m1, m2, m3, and sm1 cases; 9% in sm2 cases; and 13% in sm3 cases. The overall risk of metastasis was 9% in m3, 16% in sm1, 38% in sm2, and 64% in sm3 patients. The 5-year disease-specific survival rates were 100% in m1, m2, and m3; 90.9% in sm1; 78.8% in sm2; and 68.6% in sm3 patients. Statistically, both lymphatic and venous invasion were selected as predictive markers for metastasis. In m3 patients, positivity for either of these had an odds ratio for metastasis of 7.333 (P = 0.093). CONCLUSIONS: Our study provides a precise assessment of the comprehensive risk of metastasis and feasible predictive markers for T1 ESCC.


Subject(s)
Carcinoma, Squamous Cell/pathology , Esophageal Neoplasms/pathology , Lymphatic Metastasis , Aged , Chi-Square Distribution , Diagnostic Imaging , Esophageal Squamous Cell Carcinoma , Esophagectomy , Esophagoscopy , Female , Humans , Incidence , Logistic Models , Lymph Node Excision , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Recurrence, Local/diagnosis , Neoplasm Staging , Prevalence , Retrospective Studies , Risk , Survival Rate
20.
Int J Oncol ; 41(5): 1653-61, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22940702

ABSTRACT

The expression of microRNA-203 (miR-203) in esophageal squamous cell carcinoma (ESCC) tissues is remarkably lower than that in non­ESCC tissues. We investigated how miR-203 could influence the development of ESCC cells. Our analyses revealed that miR-203 inhibited the migration and invasion of ESCC cells. Genome-wide gene expression data and target site inhibition assays showed that miR-203 appears to directly regulate LIM and SH3 protein 1 (LASP1). The knockdown of LASP1 resulted in inhibition of the migration and invasion of ESCC cells. Our results suggest that miR-203 and its target LASP1, may be associated with the progression of ESCC. In clinical ESCC specimens, the expression levels of miR-203, which were lower compared to those in normal tissues, were inversely correlated with the mRNA expression levels of LASP1. Moreover, we found that there was a significant correlation between the expression levels of miR-203 and the relapse­free survival. The identification of a cancer network regulated by miR-203 could provide new insights into the potential mechanisms of the progression of ESCC.


Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Carcinoma, Squamous Cell/genetics , Cell Movement/genetics , Cytoskeletal Proteins/genetics , Esophageal Neoplasms/genetics , Gene Expression Regulation, Neoplastic , LIM Domain Proteins/genetics , MicroRNAs/genetics , 3' Untranslated Regions , Base Sequence , Binding Sites , Cell Line, Tumor , Cell Proliferation , Gene Expression , Humans , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...